Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder

Topics in Antiviral Medicine

Volumn 19, Issue 4, 2011, Pages 137-142

  Letendre, Scott ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CHEMISTRY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PATHOGENICITY; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; VIROLOGY; VIRUS LOAD;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; HIV; HIV INFECTIONS; HUMANS; RNA, VIRAL; VIRAL LOAD;

EID: 84859230231     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789-1799.
2. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3-16.
3. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24:1243-1250.
4. Gonzalez E, Rovin BH, Sen L, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA. 2002;99:13795-13800.
5. Becker JT, Kingsley L, Mullen J, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology. 2009;73:1292-1299.
6. Letendre S, Rosario D, Ellis R, Potter M, Woods SP. Higher levels of phosphorylated tau in CSF are associated with HIV infection, older age, antiretroviral use, and worse prospective memory. [Abstract 406.] 18th Conference on Retroviruses and Opportunistic Infections (CROI). February 27-March 2, 2011; Boston, MA.
7. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25:1747-1751.
8. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One. 2008;3:e2516.
9. Cherner M, Letendre S, Heaton RK, et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology. 2005;64:1343-1347.
10. Letendre S, Paulino AD, Rockenstein E, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis. 2007;196:361-370.
11. Knippels HM, Goodkin K, Weiss JJ, Wilkie FL, Antoni MH. The importance of cognitive self-report in early HIV-1 infection: validation of a cognitive functional status subscale. AIDS. 2002;16:259-267.
12. Chelune GJ, Heaton RK, Lehman RAW. Neuropsychological and personality correlates of patients' complaints of disability. In: Goldstein G, Tarter RE, eds. Advances in Clinical Neuropsychology. New York, NY: Plenum Press; 1986:95-126.
13. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS. 2005;19:1367-1374.
14. Nasreddine Z. The Montreal Cognitive Assessment. http://www.mocatest.org. Accessed October 19, 2011.
15. Ellis RJ, Evans SR, Clifford DB, et al. Clinical validation of the NeuroScreen. J Neurovirol. 2005;11:503-511.
16. Parsons TD, Rogers S, Hall C, Robertson K. Motor based assessment of neurocognitive functioning in resource-limited international settings. J Clin Exp Neuropsychol. 2007;29:59-66.
17. Woods SP, Iudicello JE, Dawson MS, Weber E, Grant I, Letendre SL. HIV-associated deficits in action (verb) generation may reflect astrocytosis. J Clin Exp Neuropsychol. 2010;32:522-527.
18. Best BM, Koopmans PP, Letendre SL, et al. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011;66:354-357.
19. van Praag RM, van Weert EC, van Heeswijk RP, et al. Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother. 2002;46:896-899.
20. Antinori A, Perno CF, Giancola ML, et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis. 2005;41:1787-1793.
21. Capparelli EV, Holland D, Okamoto C, et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS. 2005;19:949-952.
22. Best BM, Letendre SL, Brigid E, et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009;23:83-87.
23. Yilmaz A, Watson V, Else L, Gisslén M. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS. 2009;23:2537-2540.
24. Yilmaz A, Gisslén M, Spudich S, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One. 2009;4:e6877.
25. Letendre SL, van den Brande, Hermes A, et al. Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin Infect Dis. 2007;45:1511-1517.
26. Yeh R, Letendre S, Novak I, et al. Singleagent therapy with lopinavir/ritonavir controls HIV-1 viral replication in the central nervous system. [Abstract 381.] 14th Conference on Retroviruses and Opportunistic Infections (CROI). February 25-28, 2007; Los Angeles, CA.
27. Gutmann C, Cusini A, Günthard HF, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS. 2010;24:2347-2354.
28. Letendre S, McClernon D, Benjamin R, et al. Presence of HIV RNA in cerebrospinal fluid that is undectable with the ultrasensitive assay. [Abstract 369.] 14th Conference on Retroviruses and Opportunistic Infections (CROI). February 25-28, 2007; Los Angeles, CA.
29. Letendre S, FitzSimons C, Ellis R, et al. Correlates of CSF viral loads in 1221 volunteers of the CHARTER cohort. [Abstract 172.] 17th Conference on Retroviruses and Opportunistic Infections (CROI). February 16-19, 2010; San Francisco, CA.
30. Letendre SL, Ellis RJ, Ances BM, Mc-Cutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18:45-55.
31. Letendre S, McClernon D, Ellis R, et al. Persistent HIV in the central nervous system during treatment is associated with worse ART penetration and cognitive impairment. [Abstract 484b.] 16th Conference on Retroviruses and Opportunistic Infections (CROI). February 8-11, 2009; Montreal, Canada.
32. Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology. 2009;73:342-348.
33. Tozzi V, Balestra P, Salvatori MF, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. JAIDS. 2009;52:56-63.
34. Ellis RJ, Smurzynski M, Kunling Wu K, et al. Effects of CNS antiretroviral (ARV) distribution on neurocognitive (NC) impairment in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) study. [Abstract T-107.] 134th Annual Meeting of the American Neurological Association. October 11-14, 2009; Baltimore, MD.
35. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23:1359-1366.
36. Garvey L, Winston A, Sabin C, UK CHIC Study Group. Does cART with greater CNS penetration prevent the development of CNS opportunistic diseases? [Abstract 427.] 17th Conference on Retroviruses and Opportunistic Infections (CROI). February 16-19, 2010; San Francisco, CA.
37. Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR, III. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS. 2009;23:1893-1901.
38. Gasnault J, Lanoy E, Bentata M, Guiguet M, Costagliola D. Intracerebral penetrating ART are more efficient on survival of HIV+ patients with progressive multifocal leucoencephalopathy (ANRS CO4-FHDH). [Abstract 385.] 15th Conference on Retroviruses and Opportunistic Infections (CROI). February 3-6, 2008; Boston, MA.